Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements.
about
The European Organization for Research and Treatment of Cancer perspective on designing clinical trials with immune therapeuticsPD-1/PD-L1 blockades in non-small-cell lung cancer therapyImmune Checkpoint Blockade in Cancer TherapyImaging in Colorectal Cancer: Progress and Challenges for the CliniciansProspects of immune checkpoint modulators in the treatment of glioblastomaRadiation Therapy Intensification for Solid Tumors: A Systematic Review of Randomized TrialsOptimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab?Nuclear Molecular Imaging Strategies in Immune Checkpoint Inhibitor Therapy.Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome.The power of phase II end-points for different possible mechanisms of action of an experimental treatmentCancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment.Using lymph node swelling as a potential biomarker for successful vaccination.Accuracy and feasibility of estimated tumour volumetry in primary gastric gastrointestinal stromal tumours: validation using semiautomated technique in 127 patients.Using MRI to evaluate and predict therapeutic success from depot-based cancer vaccines.Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanomaImmune-related response evaluations during immune-checkpoint inhibitor therapy: establishing a "common language" for the new arena of cancer treatment.Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer.Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients.Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know.Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma.Checkpoint blocking antibodies in cancer immunotherapy.Ipilimumab in non-small cell lung cancer and small-cell lung cancer: new knowledge on a new therapeutic strategy.Optimal design of trials to demonstrate the utility of genomically-guided therapy: Putting Precision Cancer Medicine to the test.Immunotherapy in prostate cancer: review of the current evidence.Immunotherapy for non-small-cell lung cancer: the past 10 years.Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies.Monitoring immune-checkpoint blockade: response evaluation and biomarker development.Immunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms.Checkpoint Inhibitors for the Treatment of Hodgkin Lymphoma.iRECIST: guidelines for response criteria for use in trials testing immunotherapeuticsPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer.Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA+ Metastatic Colorectal Cancers.Immuno-Oncology: The Third Paradigm in Early Drug Development.Clinical outcome of high-dose bolus intravenous interleukin-2 with a modified administration schedule for Asian patients with metastatic renal cell carcinoma.T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma.Measurements of metastatic renal cell tumours as determined by diffusion weighted imaging or computed tomography are in close agreement, a pilot study.Immuno-oncology combinations: raising the tail of the survival curve.Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma.
P2860
Q26738677-B9E73190-1FE0-4AE6-B3A0-81A3C5EC2776Q26765024-24C15D24-E609-4CBD-BAEA-CEF0B7A99791Q26830509-F1D0738D-B22B-4255-89DC-41C3AEE97F1FQ28067562-E03C1A13-CC9A-4B79-A33E-66C1E39876BEQ28081371-ECA80D37-75FF-46B7-A0B0-DC18085C3FD7Q30278410-5DAA98D4-2EC3-4BF8-BD31-6C85A5EFEEBAQ33830113-AEDD8B1A-438C-4F36-9A23-7A2A2D0DCE5FQ33850467-2252FBAA-A640-4B5E-8416-59EE0C8BC825Q34537285-1F1885A7-F609-4B59-B522-05C4F4FD1B8EQ35619065-23E3A5C6-AE29-4D8C-B4D8-B98282E32D2AQ35668604-F8EFBC91-E4D5-417E-8465-A83841E0BBB9Q36032562-32D7A3E6-608C-4859-9EBC-B18860B28B09Q36303750-F25C31BB-D0EC-4047-B120-93C4CE931FD1Q36388915-F56F2B41-3C6D-4376-869C-F7B5D2025672Q36561655-3D060661-5990-462A-ABB5-BAB09CB405ECQ37024590-763B2D72-606C-4502-B035-5BFAC205D980Q37277324-C8DCC22B-BBC5-4D2B-80D6-645E59D52726Q37350763-D64E37A0-F3DC-4EDC-8632-9BEC475CDD94Q37516943-F7982116-2F36-47A8-8287-DFBAB9AD3683Q37589557-6AD93393-D53C-4AFE-950B-612BB572AC41Q37603380-41690535-CFF6-4D4D-9105-963A06C8F36FQ38155703-03A7DD9E-23FD-4DF3-A386-D342ACB62035Q38202161-0B46D1D3-FA32-41DA-9899-F6B09DEBFD78Q38235827-91462068-784E-489E-8A32-4CF88D6B6064Q38283918-EA612CE4-5931-465C-92A1-A8540BDA317BQ38514566-FFFD4CE2-E0B7-439E-887D-9A30DA4FA4B4Q38636711-DDB9A047-8ECD-435E-BEB4-74B4FF351EF8Q38666241-3924E236-9709-41D9-9EEE-3F4F6024904FQ38699858-64FD808C-B9FA-436E-A1B6-B772348F3FC3Q38714437-87393B55-FF8E-43D1-9564-FDC1D0BC0571Q38748974-B2105E24-419F-4C91-AA16-C7FD568B5A28Q38754407-03CA20A1-08E1-4375-ADF6-36755FA1B81EQ38861769-81985265-BBC0-4F47-8926-1F03009C9E56Q39044147-0C151C1E-860D-43CD-BCA0-A1BA378E2E90Q39067371-16495CB4-3FDC-4DA7-BD32-04BD71674788Q40248504-05EA98B2-2E92-4561-A6BA-9FB509F3A2BAQ41488571-A9ADE686-ECF6-42F7-8CBB-5302F4AB224AQ42291319-45D25622-3D1B-4169-9177-32F5ACFAE542Q42421273-D52EA590-8DEF-47F2-B5AE-285A574B8464Q45072406-DF37AF2B-D767-479A-8071-CAAD0549F4AE
P2860
Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Developing a common language f ...... g unidimensional measurements.
@en
Developing a common language f ...... g unidimensional measurements.
@nl
type
label
Developing a common language f ...... g unidimensional measurements.
@en
Developing a common language f ...... g unidimensional measurements.
@nl
prefLabel
Developing a common language f ...... g unidimensional measurements.
@en
Developing a common language f ...... g unidimensional measurements.
@nl
P2093
P2860
P1476
Developing a common language f ...... g unidimensional measurements.
@en
P2093
Anita Giobbie-Hurder
F Stephen Hodi
Margaret Suda
Maria Gargano
Mizuki Nishino
Nikhil H Ramaiya
P2860
P304
P356
10.1158/1078-0432.CCR-13-0895
P407
P577
2013-06-06T00:00:00Z